anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The future will witness the substantial worldwide growth of older people with functional limitations or disabilities who have difficulties leaving their dwellings and traveling to their neighborhoods or other community destinations to realize their obligatory and discretionary needs and goals. This commentary offers conceptual arguments and literature findings proposing that the dwellings of this vulnerable population deserve new scrutiny because they have become more salient and positively experienced places to live where their occupants can maintain their independence and age in place. The catalyst for this commentary is the emergence of gerontechnological innovations relying on digital and sensor technologies, offering these older occupants a new category of dwelling connectivity solutions-constituting a paradigm shift-whereby goods, care, services, social supports, and information and leisure activities can be delivered to their houses and apartments. Incorporating this technological component has transformed their dwellings into dynamic "control centers," connecting their occupants in real-time with the resources and activities offered in other places. These solutions enable older people to cope more effectively with declines and losses because their ability to live independently is less threatened by challenges they face accessing destinations with inadequate transportation options and less age-friendly land use or physical design features. By occupying more supportive, safer, and connected dwellings, these older people have overall more positive and salient residential mastery emotional experiences and feel more competent and in control of their lives and environment. Planning or policy recommendations directed to the World Health Organization (WHO) and its age-friendly city/community agenda follow from its conclusions. They highlight how dwelling environments containing gerontechnological solutions are becoming more critical influences of "active aging." The commentary recommends that WHO allocates more resources to dwelling interventions that increase the awareness, availability, usability, and acceptability of these gerontechnological solutions, thus reducing the disincentives for older people to be adopters.
Lactose powder encapsulated to produce a blinded product that looks identical to the other arms. Starting dose is one capsule per day, escalating to 2 capsules per day after 2 weeks if no side effects and up to 3 capsules per day after 4 weeks.
The present invention is directed to improved oral dosage form for swallowing with liquid. In one embodiment, the oral dosage form is a capsule. The capsule includes a body portion that has an opening and an interior in communication with the opening. An active ingredient is concentrated in the interior of the body portion. The capsule includes a solid filler cap portion. In one embodiment, the solid filler cap portion is digestible. The solid filler cap portion is joined to the body portion and completely covers the opening in the body portion. The solid filler cap portion has a predetermined weight that effects at least partial sinking of the capsule in the liquid with which the capsule is to be taken.
The invention provides a drug for treatment of gastric ulcer, and the drug contains galla chinensis, red halloysite, aucklandia, citrus aurantium, bighead atractylodes rhizome and furazolidone. The mass of each raw material of the galla chinensis, red halloysite, aucklandia, citrus aurantium, bighead atractylodes rhizome and furazolidone is 7-10 grams. The mass of each raw material of the drug prepared from the galla chinensis, red halloysite, aucklandia, citrus aurantium, bighead atractylodes rhizome and furazolidone can be adjusted by 3-4 grams greater or less. The galla chinensis, red halloysite, aucklandia, citrus aurantium, bighead atractylodes rhizome are crushed, and then the furazolidone is added. The e dosage formulation of the drug can be a tablet or a capsule. The drug has the effects of effective dispersing swelling, engendering flesh and astringency and hemostasis, can accelerate erythrocyte sedimentation rate so as to promote inflammation resolution, fast cure of the ulcer surface and recover. The drug has the advantages of being simple in use method and low in cost.
Lung cancer is the second most common cancer type worldwide and remains the leading cause of cancer death worldwide. Non-small cell lung cancer accounts for 80% of the total number of lung cancers, 15-55% of NSCLC have EGFR mutations, of which about 50% of Asians, targeted drugs - epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) ) showed good clinical benefit. However, patients with EGFR-mutant lung cancer experience disease progression within about a year of treatment with EGFR-TKIs, and acquired resistance develops and limits the long-term efficacy of these EGFR-TKIs. About 50% of EGFR-TKIs acquired resistance mutations by the mechanism of T790 mutation. Third-generation EGFR-TKIs can be used to overcome drug resistance against T790 mutation. Unfortunately, acquired resistance to third-generation EGFR-TKIs will eventually emerge, and when third-generation EGFR-TKIs acquire resistance, effective treatment options are still being explored. PARP (poly(ADP-ribose) polymerase) inhibitors represent a new class of anticancer therapy. They exploit synthetic lethality and induce cell death by exploiting defects in DNA repair, poly(ADP-ribose) polymerase-1 (PARP1) and poly(ADP-ribose) polymerase-2 (PARP2) are PARP enzymes Members of the family that play key roles in the DNA damage response (DDR) by acting as DNA damage sensors and signal transducers. PARP inhibitors can be used in combination with conventional NSCLC treatment regimens or as monotherapy. In clinical applications, PARP inhibitors have demonstrated sustained antitumor responses as single agents in BRCA1- or BRCA2-mutated patients. Studies have shown that the single-drug toxicity of PARP inhibitors is much lower than that of platinum drugs, and experimental results in NSCLC cell lines have shown that PARP inhibitors have single-drug activity in NSCLC. The characteristics of the domestic PARP inhibitor, Pamiparib, reflect its advantages over other PARP inhibitors: 1)low drug resistance, 2)high selectivity, 3)high capture of PARP-DNA complexes, 4)high membrane permeability, 5)Dual pathway metabolism, 6)Blood-brain barrier permeability. Multiple clinical data show that Pamiparib as a single agent has favorable safety and antitumor activity in advanced recurrent solid tumors.
PURPOSE: An agent for dyeing public hair and preventing loss of public hair and a method for manufacturing the same are provided to dye the grey public hair into black without side effect and to build self-confidence. CONSTITUTION: A method for manufacturing an agent for dyeing public hair and preventing loss of public hair comprises: a step of extracting Alnus japonica (Thunb.) Steud. bark cone to prepare Alnus japonica (Thunb.) Steud. extract; a step of preparing blood food dye; a step of mixing the Alnus japonica (Thunb.) Steud. extract and block food dye; a step of preparing bamboo extract; a step of mixing the extract, black food dye, and bamboo extract and adding Ecliptae Herba; and a step of preparing the mixture in a foam or mud form.
Patients randomized to the rhythm monitoring arm will assess their heart rhythm with a photoplethismography (PPG) based smartphone application (FibriCheck™). Measurements are performed three times daily and while experiencing symptoms. The patients start measuring immediately after discharge and continues until the scheduled postoperative consultation with the cardiologist or cardiac surgeon at 21-91days after discharge.
FIELD: cosmetology. SUBSTANCE: hair cream contains distilled monoglycerides, ethyl alcohol, glycerin, oil composition, emulsifiers, methyl and propyl esters of paraoxybenzoic acid, paraform, flavor and water, and additionally cream includes I-chlormethylsilatran. Emulsion wax and glycerin monostearate are used as emulsifiers. Used as oil composition are the following vegetable components: refined bleached castor oil, high-olein deodorized refined sunflower oil, or refined olive oil, or cotton salad deodorized oil, or kernel-fruit almond oil, or refined deodorized soya oil. All ingredients are taken in determined ratio. EFFECT: dandruff removal, hair strengthening and stimulation of its growing. 2 cl, 1 tbl
Interferon therapy is the most effective treatment for achieving clinical cure in chronic hepatitis B (CHB) patients. However, the treatment outcomes of interferon therapy are uncertain, multiple side effects can occur during treatment, and the treatment is expensive. Although these characteristics may affect patients' quality of life, research examining this topic is limited. We used a cross-sectional design to examine 100 CHB patients receiving interferon, 100 receiving nucleoside/nucleotide analogues, and 87 receiving non-antiviral treatment. Characteristic information, the Hepatitis B Quality of Life Instrument, Connor Davidson Resilience Scale, and Work Productivity and Activity Impairment Questionnaire were used to collect information. We found that quality of life in the interferon treatment group was higher than that in the non-antiviral treatment and nucleoside/nucleotide analogue treatment groups (p < 0.05). The factors influencing quality of life were resilience, presenteeism, hair loss, and antiviral treatment (p < 0.05). Although interferon therapy has some potential side effects, the results suggested that it did not negatively affect quality of life. Overall, interferon therapy did not have a major impact on CHB patients' daily lives and work.
PURPOSE: A novel transdermal preparation of dexibuprofen is provided to constantly release drug with reduced side effects. CONSTITUTION: A transdermal preparation contains dexibuprofen as an active ingredient. The transdermal preparation comprises a support layer and a storage layer with dexibuprofen which is an active ingredient, drug release controlling agent, and polymer adhesive. The transdermal preparation contains 0.3-30 weight% of dexibupropene drug storage layer, 50.0-90.0 weight% of adhesive, 0.1-30 weight% of drug release controlling agent. The adhesive is polyisobytylene(PIB), styrene-dien-styrene polymer(styrene-isoprene-styrene copolymer)(SIS). The drug release controlling agent is fatty acid ether, non-ionic surfactant, isopropylmyristate, vegetable oil(castor oil), triacetin, or fatty acid.
FIELD: medicine. SUBSTANCE: method involves applying sequestrectomy under tourniquet under general anesthesia conditions. Walls are treated with antiseptic solutions. Composition volume to be predicted is determined by filling bone cavity with antiseptic solution with following measurement carried out. Then bone defect walls are treated with 96% alcohol solution and filled with composition having liquid and dry mass. Liquid component is 15% Sulfacrylate glue solution in acetone. Dry mass is composed of an antibiotic and taken in the amount of two-days age- dependent dose and methyl uracil powder. The dry and liquid components are taken in 1:1 proportion. Methyl uracil quantity is determined as one making up 1/2 of bone defect volume when mixed with antibiotic powder. Composition quantity corresponds to the bone defect volume measured. EFFECT: prevented postoperative pyo-inflammatory complications. 4 cl
PURPOSE:An aerosol antistatic agent, suitable for clothing or hair, having softening action without causing choking due to the irritation on the mucous membrane of a respiratory organ, and containing a cationic surfactant and a nonionic surfactant at a specific weight ratio. CONSTITUTION:A cationic surfactant and a nonionic surfactant are dissolved or dispersed in a 2-3C lower alcohol at a weight ratio of the cationic to the nonionic surfactants of 1:0.1-1:2, and the resultant solution of dispersion is contained in the aerosol contents to give the total content of the surfactants of preferably 0.01- 5wt%. Thus, the aimed aerosol antistatic agent is obtained. An ammonium salt expressed by the formula [one or two of R1, R2, R3 and R4 are 8-20C (hydroxy) alkyl, and the rest are 1-3C (hydroxy)alkyl, etc.; x is halogen, 1-2C alkylsulfuric acid, etc.] is preferred as the cationic surfactant, and a polyoxyethylene adduct is preferred as the nonionic surfactant.
Sepsis is a dysregulated host response to infection that leads to life-threatening organ dysfunction. Half of the 50 million people affected by sepsis globally every year are neonates and children younger than 19 years. This burden on the paediatric population translates into a disproportionate impact on global child health in terms of years of life lost, morbidity, and lost opportunities for children to reach their developmental potential. This Series on paediatric sepsis presents the current state of diagnosis and treatment of sepsis in children, and maps the challenges in alleviating the burden on children, their families, and society. Drawing on diverse experience and multidisciplinary expertise, we offer a roadmap to improving outcomes for children with sepsis. This first paper of the Series is a narrative review of the burden of paediatric sepsis from low-income to high-income settings. Advances towards improved operationalisation of paediatric sepsis across all age groups have facilitated more standardised assessment of the Global Burden of Disease estimates of the impact of sepsis on child health, and these estimates are expected to gain further precision with the roll out of the new Phoenix criteria for sepsis. Sepsis remains one of the leading causes of childhood morbidity and mortality, with immense direct and indirect societal costs. Although substantial regional differences persist in relation to incidence, microbiological epidemiology, and outcomes, these cannot be explained by differences in income level alone. Recent insights into post-discharge sequelae after paediatric sepsis, ranging from late mortality and persistent neurodevelopmental impairment to reduced health-related quality of life, show how common post-sepsis syndrome is in children. Targeting sepsis as a key contributor to poor health outcomes in children is therefore an essential component of efforts to meet the Sustainable Development Goals.
BACKGROUND: It has been suggested that gestational diabetes mellitus (GDM) alters the growth trajectory of a fetus and increases the risk of abnormal birth weight. In spite of this, there is still a significant debate regarding the mode and optimal timing of diagnosing this condition. Our aim was to determine fetal growth velocity and birth biometry in pregnant women with GDM at varying risk levels.
METHODS: We conducted a cohort study involving 1023 pregnant women at a maternity hospital in Ma'anshan, China. All women completed an oral glucose tolerance test at 24-28 weeks' gestation. We measured fetal head circumference (HC), femoral length (FL), abdominal circumference (AC), biparietal diameter (BPD), and estimate fetal weight (EFW) by ultrasound at 17, 24, 31, and 35 weeks' gestation, respectively.
RESULTS: Overall, 5115 ultrasound scans were performed. Among both low-risk and medium-high-risk pregnant women at 17-24 weeks' gestation, GDM exposure was associated with an increase in fetal growth velocity. Neonates born to women with GDM at medium-high risk had significantly larger birth weights than those born to women without GDM, while this was not observed in women at low risk.
CONCLUSION: In medium-high-risk pregnant women, exposure to GDM has a greater effect on the fetus, leading to abnormal fetal growth velocity that lasts beyond week 24. It is evident from our results that the effects of GDM on fetal growth differ between medium-high-risk pregnant women and low-risk pregnant women, and therefore a different screening program based on the risk factor for GDM is warranted.
A 65 year-old woman, suffering from mellitus type 2 diabetes and obesity, died at home, three days after bariatric surgery (Roux-en-Y gastric by-pass: RYGB). Her treatment, including metformin and dapagliflozin, was stopped before surgery and not postoperatively reinstalled. A forensic autopsy, toxicological and histological analyses were performed. No macroscopic or microscopic evidence of digestive perforation or peritonitis was identified, excluding an early surgery complication as the cause of death. Toxicological analysis revealed the presence of Metformin in all matrices tested, with a potentially fatal blood concentration. Death was attributed to lactic acidosis caused by a metformin overdose. With no evidence for suicide by ingestion of metformin, the authors supposed that the bariatric surgery might have caused changes in the absorption of metformin, leading to a rapid overdose and death. The only study in the literature on this subject, demonstrated a significant increase in the bioavailability of metformin following oral administration in gastric bypass patients. Thus, it can be anticipated that a therapeutic dose can become toxic when administrated to a subject who recently modified her digestive equipment. As this represents the first case of metformin overdose following bariatric surgery, further cases will be needed to confirm our initial observations.
The incidence and prevalence of diabetes mellitus (DM) have increased over the last 20 years. The defining feature of diabetes mellitus (DM) is the presence of hyperglycaemia . mostly due to the progressively increasing prevalence of obesity and the metabolic syndrome, Current prevalence of DM worldwide is estimated to be about 390 million people . The Cardiovascular complications increase morbidity and mortality in diabetic patients. About 40% of end-stage renal disease on regular dialysis are diabetic . Acute kidney injury (AKI) Is a fundamental problem in hospitalized patients; its incidence has been reaching 20% in middle-Europe . About 50% of patients presented with AKI are found to be diabetic ; which may indicate a direct relationship between the two conditions. In 2012, a clinical practice guideline published by Kidney Disease: Improving Global Outcomes (KDIGO) provided a unifying definition and staging system for AKI . On the other hand, incidence of AKI in diabetic patients seems to be influenced by multiple risk Factors like severe infections, elderly, poor diabetic control, previous AKI, chronic kidney disease and drugs like SGLT2-I increase risk of AKI in diabetic patients. We aim in this study to identify the most common risk factors for AKI in diabetic patients and how those risk factors affect morbidity and mortality in patients with DM who developed AKI.
PURPOSE:To obtain the subject preparation having high drug content and high releasing rate in high efficiency by dissolving nifedipin, hydroxypropyl methylcellulose, etc., in an organic solvent, absorbing the solution in an excipient such as starch, light anhydrous silicic acid, etc., and granulating the product. CONSTITUTION:The objective nifedipin-containing solid preparation having high nifedipin content and high releasing rate can be prepared by dissolving 1 pt.wt. of nifedipin and 1.5-6 pts.wt. of hydroxypropyl methylcellulose, hydroxypropylcellulose, methylcellulose, polyvinyl pyrrolidone or a mixture of two or more of the above components in an organic solvent such as a mixture of ethanol and dichloromethane, absorbing the solution in an excipient consisting of 1-15 pts.wt. of starch, cellulose or their mixture and 2-6 pts.wt. of light anhydrous silicic acid, hydrated silicon dioxide or their mixture, granulating with a twin-screw kneader, etc., drying at 40 deg.C for 16hr, crushing the dried product and sieving to obtain fine granules having uniform particle size.
PURPOSE: To obtain an intoxication preventing agent caused by a bipyridinium type herbicide containing a hydrogenated condensed cyclic hydrocarbon of specific structure as an active ingredient and capable of effectively preventing the intoxication caused by repeatedly spraying the preventing agent without deteriorating the original purpose of the herbicide and without affecting human bodies. CONSTITUTION: The agent for preventing the intoxication, especially the chronic intoxication, caused by the bipyridinium salt type herbicide contains a bicyclic or tricyclic hydrogenated condensed cyclic hydrocarbon having at least one condensed benzene ring and a 4-8 membered ring corresponding to the condensed ring hydrocarbon on the structure of the molecule as an active ingredient. The specific hydrogenated condensed ring hydrocarbon used as the active ingredient is a hydrogenated phenanthrene (e.g. 1,2,3,4,5,6,7,8-octahydrophenanthrene), a hydrogenated anthracene (e.g. 1,2-dihydroanthracene), a hydrogenated naphthalene (e.g. 1,2-dihydronaphthalene), etc. The preventing agent is preferably added to a bipyridinium salt type herbicide and subsequently used in such the form as being inhaled on the spray of the herbicide.
The COVID-19 pandemic has profoundly impacted the mental health and developmental trajectories of children and adolescents, catalyzing a range of psychological and behavioral issues due to enforced lockdowns and other restrictions. This text explores these impacts through the lens of developmental psychopathology, which integrates clinical psychology and developmental science to examine the emergence and evolution of psychological disorders across a lifespan. This paper highlights how pandemic-related disruptions have exacerbated conditions such as anxiety and depression and, notably, increased childhood obesity due to changes in lifestyle and reductions in physical activity. The analysis includes a discussion of how isolation has not only restricted access to educational and psychological resources but also increased the risk of parental mental illness and related familial stress, thereby intensifying issues of neglect and their consequent impact on child health. By employing a developmental psychopathology framework, this paper argues for the necessity of targeted interventions that address these complex interplays of genetic, environmental, and psychological factors. Such interventions aim to support children through structured educational and health-oriented strategies, ensuring their well-being amidst the ongoing challenges posed by the pandemic. This approach underscores the importance of early, multifaceted strategies involving parents, educators, and healthcare providers to foster healthier developmental outcomes for children facing unprecedented global health crises.
Alzheimer's disease (AD) is a prevalent neurodegenerative condition affecting a substantial portion of the global population. It is marked by a complex interplay of factors, including the accumulation of amyloid plaques and tau tangles within the brain, leading to neuroinflammation and neuronal damage. Recent studies have underscored the role of free lipids and their derivatives in the initiation and progression of AD. Eicosanoids, metabolites of polyunsaturated fatty acids like arachidonic acid (AA), emerge as key players in this scenario. Remarkably, eicosanoids can either promote or inhibit the development of AD, and this multifaceted role is determined by how eicosanoid signaling influences the immune responses within the brain. However, the precise molecular mechanisms dictating the dual role of eicosanoids in AD remain elusive. In this comprehensive review, we explore the intricate involvement of eicosanoids in neuronal function and dysfunction. Furthermore, we assess the therapeutic potential of targeting eicosanoid signaling pathways as a viable strategy for mitigating or halting the progression of AD.